Menu

Call for Germline Editing Moratorium

In response to speculation that groups have edited the DNA of human embryos, researchers request that gene editing of human reproductive cells be halted.

Mar 13, 2015
Jef Akst

Human eggWIKIMEDIA, ED UTHMANGene-editing technologies should not be used to edit human eggs, sperm, or embryos, Edward Lanphier, chairman of the Alliance for Regenerative Medicine in Washington, DC, and four other researchers argued in a Nature commentary published this week (March 12). Lanphier told MIT Technology Review that the statements he and his coauthors make in their comment reflects the views of his entire organization, which includes some 200 members and represents companies working on gene and cell therapy, including GE Healthcare and Johnson & Johnson.

“In our view, genome editing in human embryos using current technologies could have unpredictable effects on future generations,” Lanphier and his coauthors wrote. “This makes it dangerous and ethically unacceptable.” Moreover, they added, such techniques could potentially be used for nontherapeutic modifications, as implied by the headline of a recent MIT Technology Review article, “Engineering the Perfect Baby,” which noted that experiments involving the editing of human embryos are “pending publication.”

Fearing that such work could elicit “a public outcry” that would impede research involving the genetic editing of somatic cells, such as the work of Lanphier and his coauthors, the researchers called for the scientific to community to halt all work involving the editing of human reproductive cells. “Philosophically or ethically justifiable applications for this technology—should any ever exist—are moot until it becomes possible to demonstrate safe outcomes and obtain reproducible data over multiple generations,” they wrote. “Should a truly compelling case ever arise for the therapeutic benefit of germ­line modification, we encourage an open discussion around the appropriate course of action,” they added, pointing to recent discussions of mitochondrial DNA replacement therapy in the U.K. as a model.

George Daley, a stem cell researcher at Boston Children’s Hospital and Harvard Medical School, agreed with the researchers’ assessment of the current state of the field. “It’s far too premature and we know far too little about the safety to make any attempts [at modifying germ cells or embryos],” he told ScienceInsider. “There needs to be broad public debate and discussion about what, if any, are the permissible uses of the technology.”

“Germline genome alterations are permanent and heritable, so very, very careful consideration needs to be taken in advance of such applications,” geneticist Dana Carroll of the University of Utah in Salt Lake City told Nature.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.